OncoGenex Announces Phase 3 SYNERGY Trial Evaluating Custirsen is Continuing as Planned

OncoGenex Pharmaceuticals OGXI today announced that the SYNERGY trial is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC). The primary registration Phase 3 SYNERGY trial is designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC). Approximately 1,023 men have been enrolled to SYNERGY at 140 sites primarily in North America and Europe. SYNERGY completed enrollment in 2012 and final survival results are expected to be announced by mid-2014. "The recommendation for SYNERGY to continue to final analysis is not surprising as the criteria to achieve statistical significance on the interim are considerably more stringent than the criteria required for the final analysis," stated Scott Cormack, President and CEO of OncoGenex.  "We do not believe these results can be interpreted to predict the final outcome of SYNERGY and we eagerly anticipate the reporting of final survival results next year." OncoGenex and custirsen co-development and commercialization partner, Teva Pharmaceutical Industries, Ltd., continue to remain blinded to all SYNERGY data and analyses, including details See full press release